ABOS News - Candlesense

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble am...

Investor conferences

about 15 hours ago

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

NEWTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics ...

Are there any notable changes in insider or institutional ownership that could signal future trading activity? What is the market's perception of Acumen's competitive positioning in the Alzheimer's treatment market following this release? How might recent regulatory developments or FDA feedback on AβO therapeutics impact Acumen's timeline and risk profile?

Earnings

15 days ago